Greater Cannabis Company, Inc. announced that it has submitted a clinical trial application to the Israel Ministry of Health for approval of a Phase 2 clinical trial for its novel neuropsychiatric cannabinoid therapy. The Company intends to conduct a Phase 2 clinical trial spearheaded by principal investigator, Dr. Adi Aran, to study the safety and efficacy of its neuroprotective cannabinoid therapeutic to treat autism related spectrum disorders (ASD) and other neuropsychiatric illnesses. The study will be conducted as a double-blind, placebo controlled trial with 100 patients ranging in age from 4-17 years old.

The study is expected to begin enrolling patients in the first half of 2023, pending approval of the Health Ministry, and to run for 12 to 18 months, including a possible open-label phase. The Company looks forward to updating shareholders on the approval of the Phase 2 study as it progresses through the review process.